About US
Contact us
-
Biosimilars look like a good bet now. But will they later? Allergan CEO says maybe notCompanies are flocking to the biosimilars scene, eager to capture a piece of the market for the world’s best-selling biologic drug brands. But one CEO won’t be surprised if those biosim developers one2017/3/8
-
Former Valeant, Philidor execs plead not guilty to multimillion-dollar fraud and kickback chargesThe former Valeant and Philidor execs accused of engineeringa multimillion-dollar fraud and kickback scheme say they did notdo it. Thursday in New York, former Valeant senior director Gary Tanner and2017/3/8
-
Roche lawsuit blasts Amgen for 'about-face' on biosimilar patent fightsBiosimilars have yet to generate really big dollars for developers, but they are certainly generating them for lawyers. In the latest legal battle, Roche’s Genentech has sued Amgen for not giving up t2017/3/7
-
What innovation? PhRMA slams Marathon after $89K pricing scandalMarathon Pharmaceuticals hasn’t made many friends in the last week. The company’s old-steroid-turned-pricey-branded-drug Emflaza touched off animmediate brouhahawhen Marathon announced its $89,000 pri2017/3/7
-
Genentech lobbyist's life and death makes pharma wavesA Genentech lobbyist who generated enormous sales for the company allegedly kept millions in consulting payments for himself and ended his own life after authorities and the company began looking into2017/3/6
-
Pfizer appeals record fine from U.K. regulator tied to 2,600% drug price hikePfizer wasted little time in challenging the record £85 million fine imposed by a U.K. cost watchdog for asupply scheme that resulted in a 2,600% price increase on an epilepsy drug sold to the N2017/3/6
-
Valeant, Ackman will split the bills for years-long Allergan shareholder suitValeant and Bill Ackman’s Pershing Square Capital Management have been battling Allergan shareholders for years over the duo’s failed hostile-takeover attempt of the company. And with the legal war st2017/3/3
-
Sanofi, Regeneron avoid Praluent disaster as appeals court stays injunction in PCSK9 patent caseRegeneron and Sanofi won’t have to pull Praluent off the market after all—at least not yet. A U.S. appeals court on Wednesdaydecidedto let the PCSK9 cholesterol drug remain on pharmacy shelves while i2017/3/3
-
Opdivo price cut may be just the beginning as Japan looks to expedite drug pricing reviewsAs it turned out, Japan’s price cut to cancer med Opdivo was not a one-off move on a pricey drug. The unconventional timing looks to be the prelude to a permanent change to the country’s drug review t2017/3/2
-
China’s healthcare reforms will shake up the country’s pharmaceutical marketThe Chinese pharma market remains one of the fastest growing, with forecasts that it will reach $167 billion by 2020. But with the Chinese government continuing to change the rules as it tries to keep2017/3/2